Acute Chest Syndrome: Clinical Trials

10 trials for Acute Chest Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 recruiting, 2 terminated. 10 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 210Completed 6, Recruiting 2, Terminated 2
Phase 31Completed 1

Follow Acute Chest Syndrome: new trials by email Literature Review of Acute Chest Syndrome trials Research Report on Acute Chest Syndrome

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
CSL889, Placebo - Sickle Cell Disease Vaso-occlusive Crisis
Phase 2RecruitingCSL Behring702025-07-102026-10-08
Tocilizumab for Acute Chest Syndrome
Tocilizumab - Sickle Cell Disease, Acute Chest Syndrome
Phase 2RecruitingUniversity of Chicago2002023-04-102026-09-15
Daily Vitamin D for Sickle-cell Respiratory Complications
Daily oral vitamin D3, 3,333 IU, Monthly oral vitamin D3, 100,000 IU, Placebo oral tablet - Sickle Cell Disease, Anemia, Sickle Cell
Phase 2CompletedColumbia University582020-09-152025-09-24
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
Defibrotide - Sickle Cell Disease, Acute Chest Syndrome
Phase 2CompletedNew York Medical College202018-01-122023-12-08
Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
Unfractionated heparin - Acute Chest Syndrome, Sickle Cell Disease
Phase 2TerminatedCraig Seaman72014-05-012019-07-16
Vitamin D for Sickle-cell Respiratory Complications
Experimental: Vitamin D3 100,000 IU, Active Comparator: Vitamin D3 12,000 IU - Sickle Cell Disease, Vitamin D Deficiency
Phase 2CompletedGary M Brittenham, MD702011-12-132024-08-09
Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children
Nitric oxide by inhalation INOMAX, Placebo - Acute Chest Syndrome, Sickle Cell Disease
Phase 2CompletedAssistance Publique - Hôpitaux de Paris212010-06-012014-12-04
Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)
Nitric Oxide, Placebo - Sickle Cell Disease, Acute Chest Syndrome
Phase 2 / Phase 3CompletedAssistance Publique - Hôpitaux de Paris1002008-12-012013-08-02
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid - Hemoglobin SC Disease
Phase 2TerminatedSt. Jude Children's Research Hospital442007-01-012013-01-18
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome
A-001, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis
Phase 2CompletedAnthera Pharmaceuticals302006-12-012014-03-04

Narrower conditions

Anemia, Sickle Cell (10)  ·  Vaso-Occlusive Crises (3)  ·  Asthma (2)  ·  Respiratory Tract Infections (2)  ·  Vitamin D Deficiency (2)  ·  Acute Kidney Injury (1)  ·  Acute Lung Injury (1)  ·  Anemia, Hemolytic (1)  ·  Anemia, Hemolytic, Congenital (1)  ·  Avitaminosis (1)  ·  Hemoglobin SC Disease (1)  ·  Hemoglobinopathies (1)  ·  Lung Diseases (1)  ·  Nutrition Disorders (1)

Broader conditions

Anemia (10)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10)  ·  Genetic Diseases, Inborn (10)  ·  Hematologic Diseases (10)  ·  Hemic and Lymphatic Diseases (10)  ·  Anemia, Hemolytic (9)  ·  Anemia, Hemolytic, Congenital (9)  ·  Hemoglobinopathies (9)  ·  Lung Diseases (9)  ·  Respiration Disorders (9)  ·  Respiratory Tract Diseases (9)  ·  Bronchial Diseases (2)  ·  Deficiency Diseases (2)  ·  Hypersensitivity (2)  ·  Hypersensitivity, Immediate (2)

Interventions

Cholecalciferol (2)  ·  Administration, Oral (1)  ·  Endothelium-Dependent Relaxing Factors (1)  ·  Hemopexin (1)  ·  Heparin (1)  ·  Hydroxyurea (1)  ·  Nitric Oxide (1)  ·  Pyrrolidonecarboxylic Acid (1)  ·  defibrotide (1)  ·  tocilizumab (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (2)  ·  Anthera Pharmaceuticals (1)  ·  CSL Behring (1)  ·  Columbia University (1)  ·  Craig Seaman (1)  ·  Gary M Brittenham, MD (1)  ·  New York Medical College (1)  ·  St. Jude Children's Research Hospital (1)  ·  University of Chicago (1)

Countries

United States (8)  ·  France (2)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)

Top investigators

Craig D Seaman, MD (1)  ·  Gabrielle Lapping-Carr, MD (1)  ·  Gary Brittenham, MD (1)  ·  Gary M Brittenham, MD (1)  ·  Malika Benkerrou, Dr. (1)  ·  Margaret Ragni, MD, MPH (1)  ·  Margaret T Lee, MD (1)  ·  Margaret T. Lee, MD (1)  ·  Mitchell S Cairo, MD (1)  ·  Winfred C. Wang, MD (1)

Results publications

PMID 21275961, PMID 26431718, PMID 29712666

NIH funding

U54HL070587 (1)